Evidence map›Paper›PMID 27068091›Full record

ArticleInfection and immunity2016

Type I Interferon Counters or Promotes Coxiella burnetii Replication Dependent on Tissue.

Jodi F Hedges, Amanda Robison, Emily Kimmel, Kelly Christensen, Erin Lucas, Andrew Ramstead, Mark A Jutila

Open access · bronzeAbstract read
In one paragraph

Article in Infection and immunity, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
1.7field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 18 citations in OpenAlex.

  1. bioRxiv : the preprint server for biology · 2026
    Article
  2. Review
  3. Review
  4. Article
  5. Infection and immunity · 2024
    Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Recent Advances on the Innate Immune Response toFrontiers in cellular and infection microbiology · 2021
    Review
  11. Article
  12. Article
  13. Review
  14. Article
  15. Review
  16. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Jodi F HedgesDepartment of Microbiology and Immunology, Montana State University, Bozeman, Montana, USA jodi.hedges@gmail.com.
Amanda RobisonDepartment of Microbiology and Immunology, Montana State University, Bozeman, Montana, USA.
Emily KimmelDepartment of Microbiology and Immunology, Montana State University, Bozeman, Montana, USA.
Kelly ChristensenDepartment of Microbiology and Immunology, Montana State University, Bozeman, Montana, USA.
Erin LucasDepartment of Microbiology and Immunology, Montana State University, Bozeman, Montana, USA.
Andrew RamsteadDepartment of Microbiology and Immunology, Montana State University, Bozeman, Montana, USA.
Mark A JutilaDepartment of Microbiology and Immunology, Montana State University, Bozeman, Montana, USA.
Montana State University · US

Funding

VIRUSES: FROM PARTICLES TO PROTEOMICSP20RR020185 · NCRR · MONTANA STATE UNIVERSITY - BOZEMAN · PI QUINN, MARK T · 2004 to 2011
$17.0M
CAMs as counter measures against infectious and inflammatory diseaseP01AT004986 · NCCIH · MONTANA STATE UNIVERSITY - BOZEMAN · PI JUTILA, MARK A · 2008 to 2012
$5.9M
Role of type I IFN and human TLR4 in Coxiella burnetii pathogenesisR21AI117441 · NIAID · MONTANA STATE UNIVERSITY - BOZEMAN · PI JUTILA, MARK A · 2016 to 2017
$396k
Role of Toll-like receptors in Coxiella burnetii infectionR21AI094261 · NIAID · MONTANA STATE UNIVERSITY - BOZEMAN · PI JUTILA, MARK A · 2012 to 2013
$385k
NCCIH NIH HHS P01 AT004986NCRR NIH HHS P20 RR020185NIAID NIH HHS R21 AI094261NIAID NIH HHS R21 AI117441
6 · The paper itself

Abstract

Coxiella burnetii is an intracellular pathogen and the cause of Q fever. Gamma interferon (IFN-γ) is critical for host protection from infection, but a role for type I IFN in C. burnetii infection has not been determined. Type I IFN supports host protection from a related pathogen, Legionella pneumophila, and we hypothesized that it would be similarly protective in C. burnetii infection. In contrast to our prediction, IFN-α receptor-deficient (IFNAR(-/-)) mice were protected from C. burnetii-induced infection. Therefore, the role of type I IFN in C. burnetii infection was distinct from that in L. pneumophila Mice treated with a double-stranded-RNA mimetic were protected from C. burnetii-induced weight loss through an IFNAR-independent pathway. We next treated mice with recombinant IFN-α (rIFN-α). When rIFN-α was injected by the intraperitoneal route during infection, disease-induced weight loss was exacerbated. Mice that received rIFN-α by this route had dampened interleukin 1β (IL-1β) expression in bronchoalveolar lavage fluids. However, when rIFN-α was delivered to the lung, bacterial replication was decreased in all tissues. Thus, the presence of type I IFN in the lung protected from infection, but when delivered to the periphery, type I IFN enhanced disease, potentially by dampening inflammatory cytokines. To better characterize the capacity for type I IFN induction by C. burnetii, we assessed expression of IFN-β transcripts by human macrophages following stimulation with lipopolysaccharide (LPS) from C. burnetii Understanding innate responses in C. burnetii infection will support the discovery of novel therapies that may be alternative or complementary to the current antibiotic treatment.

Indexed as

Host-Pathogen InteractionsAnimalsAptamers, NucleotideBronchoalveolar Lavage FluidCoxiella burnetiiDisease Models, AnimalGene Expression RegulationHumansImmunity, InnateInjections, IntraperitonealInterferon-alphaInterleukin-1betaLegionella pneumophilaLipopolysaccharidesMacrophages, AlveolarMiceAptamers, NucleotideIfnar1 protein, mouseIL1B protein, mouseInterferon-alphaInterleukin-1betaLipopolysaccharidesReceptor, Interferon alpha-betaRecombinant Proteins

Identifiers

PMID27068091
PMCPMC4907146
OpenAlexW2395292398

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.